Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Simcere Pharmaceutical Group
Simcere Pharmaceutical Group
Activities:
Ingredients
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
Merck and Simcere dissolve cardiovascular and metabolic joint venture
An explosion in the online market for drugs in China cited as a key factor in the decision
Simcere Pharmaceutical Group appoints Chief Scientific Officer
Dr Zang Jingwu to lead research and development team
Finance
Chinese drug majors look to the West to build brands
In China, large drug manufacturers are seeking partnerships, mergers and acquisitions with Western companies, writes Asia correspondent A Nair
Buyouts prove popular in China
Chinese pharma companies turning to private capital
Simcere appoints a chief executive
Hongquan Liu takes up the position next month
Research & Development
Bristol-Myers Squibb announces second pact with Simcere
The firms will co-develop BMS-795311, a preclinical small molecule CETO inhibitor
Finance
Merck and Simcere agree joint venture
Will initially offer drugs for cardiovascular and metabolic diseases
Subscribe now